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Abstract
Our understanding of epigenetics has been transformed in recent years by the advance of technological
possibilities based primarily on a powerful tool, chromatin immunoprecipitation (ChIP). However, in
many cases, the detection of epigenetic changes requires methods providing a high-throughput (HTP)
platform. Cytometry has opened a novel approach for the quantitative measurement of molecules,
including PCR products, anchored to appropriately addressed microbeads (Pataki et al. 2005. Cytometry
68, 45–52). Here we show selected examples for the utility of two different cytometry-based platforms of
epigenetic analysis: ChIP-on-beads, a flow-cytometric test of local histone modifications (Balint et al.
2005. Mol. Cell Biol. 25, 5648–5663), and the laser scanning cytometry-based measurement of global
epigenetic modifications that might help predict clinical behavior in different pathological conditions. We
anticipate that such alternative tools may shortly become indispensable in clinical practice, translating the
systematic screening of epigenetic tags from basic research into routine diagnostics of HTP demand.
Key words: Chromatin immunoprecipitation (ChIP), flow cytometry, ChIP-on-beads, laser
scanning cytometry (LSC).
1. Introduction
Epigenetic changes associated with gene regulation play a major
role in the establishment of altered differentiation states (3).
Specific modifications often correlate with gene activation or
repression; for instance H3K4ac and H3K4me3 are permissive
for gene activation whereas H3K9me2, H3K27me3, and methyla-
tion of CpG islands in promoter regions correlate with transcrip-
tional silencing. Often, activating and repressive marks co-exist at
gene start sites, reflecting perhaps epigenetic heterogeneity among
otherwise similar cells, establishing a fine balance that could deter-
mine the gene expression patterns in the tissue.
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The ‘epigenetic code’ has become an indispensable concept in
basic research, and its principles are also utilized to develop drugs
and diagnostic tools. Several genes being epigenetically misregu-
lated have been shown to associate with different kinds of cancer,
highlighting the role of the ‘language’ of covalent modifications in
tumorigenesis (4, 5). For instance, based on the patterns of mod-
ifications, two disease subtypes with different risks of tumor recur-
rence have been characterized in prostate cancer patients,
independently from tumor stage, preoperative prostate-specific
antigen levels, and capsule invasion (6).
The chromatin of cancer cells often exhibits both an overall (glo-
bal) DNA hypomethylation and hypermethylation of specific regions,
leading to ‘DNA methylation imbalance’ (7). The recurrence of global
DNA hypomethylation in many types of human cancer is suggestive of
its significant role in carcinogenesis, perhaps by inducing genomic
instability and/or activating oncogenes (8, 9). However, global hypo-
methylation is subject to a high degree of variability, unaccounted for
by our current level of understanding (10, 11). In addition to neoplas-
tic transformation, problems of epigenetic regulation, including CpG
methylation disorders are also involved in a wide range of pathological
phenomena (12, 13). In most eukaryotes, methylation of DNA occurs
at the cytosine residues of cytosine-phospho-guanine (CpG) dinucleo-
tides. The enzymes responsible for the production of 5-methylcytosine
(5-mc) involving the fifth carbon atom of cytosine in CpG dinucleo-
tides are the DNA methyltransferases DNMT1, DNMT3a, and
DNMT3b, of which the first is involved in the maintenance of methy-
lation during DNA replication, while all appear to be important in the
establishment of methylation patterns in most physiological and patho-
logical settings (14–16).
1.1. Flow- and Laser
Scanning Cytometry in
Epigenetics Research
Our understanding of epigenetics has been transformed in recent
years by a succession of technological innovations. Approaches
involving microarrays and, most recently ultra-high throughput
(deep) sequencing technology have been applied to map cytosine
methylation, chromatin modifications, and ncRNAs across entire
genomes. Genome-scale studies of histone modifications and
other aspects of chromatin structure typically rely on an immuno-
logical procedure, chromatin immunoprecipitation (ChIP) (17),
in which specific antibodies are used to enrich chromatin. ChIP is a
powerful tool in epigenetics; however, in many cases the detection
of epigenetic changes or transcription factor binding associated
with the regulation of certain genes would require ChIP-based
methods that provide high-throughput (HTP) potential. Moni-
toring local as well as global changes of epigenetic markers could
be extremely useful in diagnostics as well as in basic research.
Flow-cytometric analysis provides a novel means for the quanti-
tative measurement of molecules also in cell-free solutions, anchoring
them to appropriately addressed microbeads. The utility and power




































































approach has been demonstrated in the case of various assays
of molecular diagnostic value: immunoassays, sensitive measurement
of protease or nuclease activity, detection of deletion/insertion of
sequences by heteroduplex analysis, etc., that could all be adapted to a
‘lab-on-beads’ platform, i.e., the flow-cytometric analysis of
microbead-captured macromolecules (1, 18, 19). Many samples can
be simultaneously analyzed in a FACSarray instrument using fluor-
escent dyes matching its optical channels.
Beyond lending a HTP platform for the analysis of gene-
specific epigenetic markers, cytometry also makes global analysis
of epigenetic changes possible, most conveniently in its on-slide
format, by microscope-based cytometers. Laser scanning cytome-
try (LSC) provides a robust method for analyzing single-cell events
on slides (20, 21). It generates quantitative fluorescence data
similar to flow cytometry, but the analyzed cells are attached to
the surfaces of microscopic slides or culture chambers. The main
advantages of LSC are that (i) the possible correlation between the
simultaneously measured parameters is detected at the individual
cell resolution, i.e., with a sensitivity surpassing that of flow cyto-
metry; (ii) the instrument is able to relocate each cell for additional
measurements, thus the analysis of functional features of live cells
can be combined with measurements that require fixed cells; and
(iii) measurements can be performed in an automated fashion, pre-
programmed for several slides.
Examples highlighted in this review demonstrate the value of
two different HTP platforms for epigenetic analysis, namely ChIP-
on-beads and assessment of global epigenetic traits by LSC. These
methods might help introduce systematic screening of different
epigenetic tags into clinical practice, especially of those that corre-
late with therapeutic success. It will be shown that sequence-
specific capture of PCR-amplified ChIP-fragments on microbeads
allows a robust detection of histone-tail modifications in the pro-
moter region of a well-characterized gene, tissue transglutaminase
type 2 (TGM2). We also assess the prospects of laser scanning
cytometry for the analysis of epigenetic changes involving the





We have investigated the cellular levels of H4K acetylation and
H3K4 methylation of the histone tails at the promoter of the
TGM2 gene, to test whether these covalent modifications can be
detected using a flow-cytometric platform. As shown earlier
(2)and briefly recapped herein, the flow-ChIP method, nick-
named ChIP-on-beads, can be easily implemented in a routine
flow-cytometric clinical laboratory without relying on real-time
QPCR. In the ChIP-on-beads assay, a standard ChIP is performed
and then this DNA is used as template in an end-point PCR
reaction. The sense and anti-sense primers are tagged at their 50
ends with fluorescent dyes (e.g., Fam, Cy3) and biotin,
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respectively. Small aliquots of the Fam/biotin-ended PCR products
are then bound to streptavidin-conjugated microbeads and quanti-
fied by flow cytometry. Of note, PCRs must be stopped in the linear
phase to ensure reliable quantification; this should be initially deter-
mined in pilot QPCR experiments. The similarity of data obtained
by QPCR and by flow cytometry has been shown (2).
As shown in Fig.7.1A, the fluorescence intensity of the
microbeads increases linearly with the quantity of the fluorescei-
nated PCR products added, allowing the expression of ChIP-PCR






































H4Kac % of input
H3K4me2% of input
TGM2 eto
Fig. 7.1. Analysis of gene specific histone modifications by ChIP-on-beads. (A) Calibration curve (FL-1 vs. log copy
number) based on a dilution series of known quantities of Fam/biotin-tagged PCR products. TGM2 copy numbers of ChIP-
PCR samples were determined by reference to this standard curve. (B,C) ChIP-on-beads analysis of H4Kac and H3K4me2
histone modifications at the TGM2 g ene promoter and at exon 9 of the MLL gene, in Jurkat cells. Apoptosis was induced
by etoposide treatment (Eto). (B) Flow-cytometric fluorescence distribution histograms of Fam/biotin-labeled ChIP-PCR
samples captured on streptavidin-conjugated microbeads. (C) The level of modified histones within the TGM2 and MLL
genes are expressed as percent of input values (Y axis), based on the means of fluorescence distribution and after


































































yields as absolute copy numbers. The flow-cytometric fluorescence
distribution means are used to calculate the fraction of DNA copy
numbers in the ChIP samples relative to the input DNA
(Fig.7.1B). Comparing control and early-apoptotic Jurkat cells
for changes in the level of H4Kac and H3K4me within the pro-
moter of TGM2, we observed a significant decrease in both histone
modifications (Fig.7.1C), suggestive of the closure of chromatin
structure early upon apoptosis. In comparison, the observed his-
tone modifications at exon 9 of the MLLgene, used as positive
control, were in accordance with its known histone-code profile
(22); in contrast, the b-globin gene, used as negative control, gave






It is often important to consider in what global context local
epigenetic changes occur (23). Moreover, global changes of cer-
tain epigenetic modifications may have their independent diagnos-
tic value, especially when analyzed in correlation with other
phenotypic markers, an opportunity offered by up-to-date laser
scanning microscopic systems (20, 21). Development of antibo-
dies and chimeric methyl CpG-binding antibody-like proteins
(24–27), both recognizing CpG with high specificity, has opened
novel perspectives for the diagnostic analysis of global methylation
states. Anti-5mC antibodies are commercially available through
various sources (e.g., Abcam and Biocarta US).
In experiments using the recombinant mCpG-binding anti-
body-like MBD-Fc protein (26–28), the overall level of CpG
methylation has been quantified in the HCT116 cell line
(Fig.7.2). As shown by confocal laser scanning microscopy











































Fig. 7.2. Global DNA methylation analyzed by confocal laser scanning microscopy and laser scanning cytometry. WT: wild-
type DNMT1/DNMT3b HCT116 cells immunolabeled with the MBD-Fc fusion protein. K.O.: dnmt1/dnmt3b knock-out
HCT116 cells immunolabeled with the MBD-Fc fusion protein. Left slides: DNA stained by Hoechst. Right slides:
methylated DNA (mCpGs). (A) Methylated CpG dinucleotides visualized by confocal laser scanning microscopy (CLSM).
(B) Sample analyzed by laser scanning cytometry (LSC). MCpG (red) fluorescence was quantified in the slide-attached
cells (n>400) and presented (in arbitrary units) as fluorescence distribution histograms.

































































(CLSM), mCpGs have been efficiently labeled by indirect immu-
nofluorescence in DNMT1/3b wild-type and, to a lesser extent,
DNMT/3b double knock-out cells. The level of mCpGs has been
quantified in a sizable population of cells by an iCys laser scanning
cytometer and iCyte 2.6 software (CompuCyte, USA). As shown in
Fig.7.2, the fluorescence distributions of the Alexa546-labeled
mCpGs are significantly different in the DNMT1/3b+/ cells; this
result demonstrates the utility of LSC for the fine assessment of
global methylation states in different cell types (e.g., differentiated
vs. stem cells) or in a specific cell type (e.g., in human peripheral
lymphocytes isolated from blood samples) before and after drug
treatment or chemotherapy. Since LSC can be performed in an
automated fashion, such studies could be made on large sets of
biopsy material so as to establish the exact role of global DNA
methylation in human pathological diagnosis of various diseases.
Data presented herein have demonstrated that if combined,
flow cytometry and conventional PCR offer a powerful tool in the
quantitative analysis of ChIP results. We have found high levels of
H4Kac and H3K4me at the TGM2gene core promoter (Fig.7.1).
These levels significantly decreased upon apoptosis and this was
accompanied by the down-regulation of TGM2 mRNA expression
(2), suggesting that this enzyme does not contribute to the early
manifestations of apoptosis in Jurkat cells. Differences in the global
level of DNA methylation in HCT116 wild-type and methylation
defective cells have been revealed by LSC, the on-slide version of
flow cytometry (Fig.7.2). Both assays can be easily implemented,
and readily applied in a HTP format. We envisage the utility of
these platforms primarily in clinical screening efforts addressing
one, or a few, epigenetic markers in many samples simultaneously,
depending on cost/time considerations and availability of instru-
mentation/expertise.
Although the epigenetic changes are heritable, they appear
to be readily reversed by specific drug treatments as opposed to
gene mutations. We expect that the epigenetic silencing of, e.g.,
tumor suppressor genes will soon become a frequent target of
HTP screening studies because these mechanisms may be as
important in carcinogenesis as the inactivating mutations. Drugs
targeting the enzymes that remove or add these chemical tags are at
the forefront of research: diseases to be targeted include cancer,
imprinting disorders, autoimmune diseases, certain neurological
disorders, diabetes, cardiopulmonary diseases, in which mis-steps
in epigenetic programming have been directly implicated. Pharma-
ceutical companies have set up programs on histone decacetylases
(HDACs) and DNA methyltransferases (DNMTs) and their inhi-
bitors, as they have the potential to re-activate specific tumor
suppressor genes; clinical trials being on the way are promising
the prospect of eliciting tumor regression by modulation of epige-
netic regulation.AQ2


































































Based on the above, we anticipate that epigenetic analysis will
enter routine diagnostic practice whenever monitoring epigenetic
markers can help predict clinical behavior. When large sets of
samples are to be assessed, high-throughput platforms for the
accurate evaluation of the ChIP results are of general interest. In
view of the fact that most routine techniques can be adapted to
flow cytometry which exceeds more conventional methods in
sensitivity and reproducibility, the approaches shown can provide
a universal platform for almost any kind of lab purposes. Whether
ChIP-QPCR, ChIP-on-beads, or LSC-based assays of global epi-
genetic changes will be selected as the approach of choice for such
screening projects will be determined by the particular task under-
taken, and the capabilities of the clinical laboratories. We believe
that these alternative ChIP platforms can help bring epigenetic
analysis within reach for routine laboratories, especially for those
involved in clinical diagnostics.
2. Materials
2.1. Cell Culture 1. McCoy’s medium (Sigma-Aldrich).
2. Solution of trypsin: stock solution at 0.5%, working solution
at 0.05% in 1X phosphate buffered saline (PBS); store at –
20C.
3. Glutamine: stock solution at 200 mM, final concentration at 2
mM in ddH2O; store at –20C.
4. Etoposide (Sigma-Aldrich): stock solution at 40 mM, work-
ing concentration at 40 mM.
2.2. Detection
of Methylated CpGs by
Immunofluorescence
1. 1X PBS: 1.37 MNaCl, 27 mMKCl, 100 mMNa2HPO4, 18
mMKH2PO4; adjust to pH 7.4 with HCl if necessary.
2. Labeling solution: 1X PBS/10%BSA; store at –20C.
3. Primary antibody (1.9 mg/mL): MBD-Fc, a recombinant
antibody which was made of human MBD domain (methyl
binding domain) fused with an Fc fragment of a human
IgG1 and expressed in Drosophila S2 cells (26–28); store
at 4C.
4. Secondary antibody (2 mg/mL): Alexa546-conjugated anti-
human IgG (Invitrogen); store at 4C.
5. Hoechst 33342 (Invitrogen): stock solution: 1 mM, working
solution: 4 mM, final concentration: 2 mM, diluted in 1X PBS;
store at –20C.
6. Prolong Gold (Invitrogen).
SPB-152001 7 May 4, 2009 Time: 9:52 Proof 1


































































1. Nucleus isolation buffer: 5 mMpipes, pH 8.0, 85 mMKCl,
0.5% NP-40, protease inhibitors (Sigma-Aldrich, cat no.
P8340).
2. Sonication buffer: 1% SDS, 10 mMEDTA, 50 mMTris-HCl,
pH 8.0, protease inhibitors.
3. IP buffer: 0.01% SDS, 1.1% Triton X-100, 1.2 mMEDTA, 20
mMTris-HClAQ3 pH 8.0, 167 mMNaCl, protease inhibitors.
4. Blocked protein A/G Sepharose (Upstate, cat. no. 16-157).
5. Antibodies (Upstate): anti-H4Kac, 2 mg/IP (cat. no. 06-
866), anti-H3K4me2, 5 mg/IP (cat. no. 07-030).
6. Wash buffer (WB) A: 0.1% SDS, 1% Triton X-100, 2 mM
EDTA, 20 mMTris-HCl, pH 8.0, 150 mMNaCl, protease
inhibitors.
7. WB B: 0.1% SDS, 1% Triton X-100, 2 mMEDTA, 20
mMTris-HCl, pH 8.0, 500 mMNaCl, protease inhibitors.
8. WB C: 0.25 MLiCl, 1% NP-40, 1% Na-deoxycholate, 1
mMEDTA, 10 mMTris-HCl, pH 8.0, protease inhibitors.
9. 1X TE: 10 mMTris-HCl, pH 7.5, 1 mMEDTA.
10. QIAquick PCR Purification Kit (Qiagen).
11. Primers: forward 50-Fam-GAGACCCTCCAAGTGCGAC-30,
reverse 50-Biotin-CCAAAGCGGGCTATAAGTTA GC-30.
12. Streptavidin-coated microbeads (6 mm, Polyscience).
3. Methods
3.1. ChIP-on-Beads 1. Treat exponentially growing Jurkat cells with 40 mMetopo-
side (eto) for 3 h at 37C to induce apoptosis.
2. Fix cells with 1% formaldehyde for 10 min at room tempera-
ture. Stop fixation by adding 2.5 M glycine to a final concen-
tration of 0.67 M, for 5 min at room temperature. Wash cells
twice in ice-cold PBS.
3. Resuspend cells in 1 mL of nucleus isolation buffer and incu-
bate them for 10 min on ice. Vortex tubes in every 2–3 min.
4. Centrifuge isolated nuclei at 500g for 3 min, at 4C. Resus-
pend pellet in 500 mL sonication buffer.
5. Sonicate chromatin to an average fragment size of 500 bp
using a Bioruptor (Diagenode); 0.5 min ON/0.5 min OFF
pulses for 2  12 min usually produces the desired size
distribution.


































































6. Centrifuge sheared chromatin samples at maximum speed for
20 min. Keep supernatants (leave 50 mL on the bottom of the
tubes). Freeze in liquid nitrogen and store samples at –80C
(or proceed immediately).
7. Thaw samples on ice and centrifuge them at maximum speed
for 10 min at 4C. Transfer supernatants into clean tubes (do
not disturb pellet on the bottom of the tubes).
8. Dilute chromatin samples 1:10 in IP buffer as follows: 100 mL
chromatin 900 mL IP buffer.
9. Pre-clear samples by incubating them on a rotating wheel with
30 mL of blocked protein A/G Sepharose for 30 min at 4C.
Spin samples at 500g for 3 min at 4C. Keep supernatants.
10. Perform immunoselection for >12 h on a rotating wheel by
adding the following antibodies to the samples: anti-H4Kac
and anti-H3K4me2; as negative control, omit specific Ab but
add a specific IgG protein from the same isotype to one of the
pre-cleared samples.
11. Preserve 10 mL from the ‘negative control’ as ‘input’ DNA
and store it at –20C. Collect immune complexes by adding
40 mL of blocked protein A/G Sepharose to each sample and
incubate them for 45 min on a rotator. Spin samples at 500g
for 3 min.
12. Wash the pelleted immune complexes as follows: 2 WB A,
2 WB B, 2 WB C, 1 TE. Resuspend pellets in 500 mL
TE. At this point thaw input DNA and dilute it to 500 mL;
process it together with the IP samples.
13. Reverse cross-links by incubating the samples at 98C for
10 min. Put samples on ice.
14. Digest residual RNAs with 200 mg/mL RNase A for 30 min at
37C.
15. Digest proteins by 0.5 mg/mL proteinase K for at least 2 h at
55C.
16. Purify DNA on PCR clean-up columns (Qiagen). Immuno-
precipitated DNA samples (input, negative control, H4Kac/
H3K4me2, respectively) are ready to be tagged by Fam/
biotin PCRAQ4 .
17. In the Fam/biotin PCR, use primers listed in Section2.3.
Perform PCRs under standard conditions and stop after
15–20 cycles, i.e., in the linear phase. Validate by QPCR
(2). Purify the 50-Fam/biotin labeled ChIP-PCR products
on PCR clean-up columns.
18. Carry out flow cytometry on a Becton-Dickinson FACScan
flow cytometer as follows: 5 mL of the Fam/biotin-tagged
ChIP-DNA was added to 10,000 streptavidin-coated, plain
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beads in 50 mL PBS. Incubate samples for 15 min at room
temperature, wash in 1 mL PBS, and run at high speed. Set
laser power to 15 mW and detect fluorescence signals through
the 530/30 interference filter of the FL1 channel in logarith-
mic mode. Evaluate results using the BDIS CELLQUEST 3.3
(Becton-Dickinson) software. TGM2 copy numbers are deter-
mined by reference to a standard curve obtained from a dilu-
tion series of known quantities of Fam/biotin-tagged PCR
products (Fig.7.1A). Express ChIP yields as percentage of






1. Grow HCT116 DNMT1/3b wt and DNMT1/3b knock-out
cells on coverslips overnight.
2. Wash cells in 200 mL 1X PBS, 3  3 min.
3. Fix cells in a series of diluted methylalcohol (MetOH) (as
shown below); wash cells with 200 mL of diluted MetOH
once for 3 min, for each dilution. Start with the 10 dilu-
tion. After washes, incubate cells in concentrated MetOH
overnight at –20C.
1X PBS (mL) MetOH (mL)
10 MetOH 900 100
8 MetOH 875 125
6 MetOH 833 167
4 MetOH 750 250
2 MetOH 500 500
4. Rehydrate cells in a series of diluted 1X PBS as shown below;
wash cells in 200 mL diluted MetOH for 3 min in each
dilution. Start with the 10 dilution. After the final rehydra-
tion step, wash with 200 mL 1X PBSs
MetOH (mL) 1X PBS (mL)
10 (1X PBS) 900 100
8 (1X PBS) 875 125
6 (1X PBS) 833 167
4 (1X PBS) 750 250
2 (1X PBS) 500 500


































































5. In order to relax DNA, place samples into Petri dishes (with-
out the cover) in PBS/1% BSA and irradiate them with UV
light for 30 min.
6. Immunolabel samples using the mCpG-specific MBD-Fc
fusion protein or a commercially available Anti-5mC as pri-
mary antibody for 30 min at room temperature. Wash cells in
200 mL of 1% BSA/PBS, 3 for3 min.
7. Label samples with an Alexa546-conjugated anti-human IgG
secondary antibody, for 30 min at room temperature. Wash
cells in 200 mL 1% BSA/PBS 3 for 3 min.
8. Stain DNA with 50 mL Hoechst 33342 (2 mM) and cover with
Prolong Gold antifade.
9. Scan slides (see Note 1).
4. Notes
1. MCpGs have been visualized using a Zeiss LSM 510 confocal
laser-scanning microscope using excitation wavelengths of
543 and 351/364 nm. Fluorescence emission was detected
through 560–615 and 385–470 nm band-pass filters. Images
were taken in multitrack mode to prevent cross-talk between
the channels. Pixel image (512  512) stacks of 2–2.5 mm
thick optical sections were obtained with a 63 Plan-
Apochromat oil immersion objective (NA 1.4).
The same samples were also analyzed using an iCys laser scan-
ning cytometer (CompuCyte). The instrument used in our
studies is equipped with a violet-blue diode, an argon-ion, and
a HeNe laser (wavelengths 405, 488, and 633 nm, respec-
tively). The violet and Ar-ion laser lines were used for excita-
tion of Hoechst and Alexa 546 dyes. To identify single nuclei,
contouring was based on Hoechst fluorescence detected in the
blue channel (460–485 nm). Fluorescence of Alexa 546
(MCpGs) was detected in the orange channel (565–585 nm)
based on the contour gained in the blue channel. In single
nuclei identified by contouring on fluorescence of the nuclear
stain, the integral fluorescence related to the MCpGs divided
by the area of the contour was used to describe the methyla-
tion level. This corrects for differences in nuclear size. Data
evaluation and hardware control were performed using the
iCys 2.6 software for Windows XP. Using the 4 objective
to scan an indicated area on a slide, 400–1000 cells were
scanned in about 10 min (21). LSC can screen relatively
large number of cells on a slide. The cells are distinguished
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based on their fluorescence properties like in flow cytometry.
However, as the position of each cell is fixed on the slide and
the instrument saves the positional information, any correla-
tion between the different parameters measured can be
detected in a very sensitive manner. In addition, the cells can
be relocated and visually analyzed or re-scanned after re-stain-
ing with conventional stains or fluorescent markers.
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